Chimeric antigen receptor T-cell therapy induces complete remission in a patient with concurrent CLL with CNS involvement and multiple sclerosis.

IF 2.1 4区医学 Q3 HEMATOLOGY

Leukemia & Lymphoma Pub Date : 2026-08-01 Epub Date: 2026-06-07 DOI:10.1080/10428194.2026.2682293

Dermot J Murphy, Siba El Hussein, Angela Applebee, Alissa Thomas, James N Gerson

引用次数: 0

Abstract

In a patient with chronic lymphocytic leukemia (CLL) involving the central nervous system, and concurrent multiple sclerosis (MS), CD19-directed CAR T-cell therapy led to complete remission of CLL and marked improvement in MS disease burden.

查看原文本刊更多论文

嵌合抗原受体t细胞治疗诱导CLL合并中枢神经系统累及多发性硬化症患者完全缓解。

在一名慢性淋巴细胞白血病（CLL）累及中枢神经系统并并发多发性硬化症（MS）的患者中，cd19导向的CAR - t细胞治疗导致CLL完全缓解，MS疾病负担显著改善。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Leukemia & Lymphoma 医学-血液学

CiteScore

4.10

自引率

3.80%

发文量

384

审稿时长

1.8 months

期刊介绍： Leukemia & Lymphoma in its fourth decade continues to provide an international forum for publication of high quality clinical, translational, and basic science research, and original observations relating to all aspects of hematological malignancies. The scope ranges from clinical and clinico-pathological investigations to fundamental research in disease biology, mechanisms of action of novel agents, development of combination chemotherapy, pharmacology and pharmacogenomics as well as ethics and epidemiology. Submissions of unique clinical observations or confirmatory studies are considered and published as Letters to the Editor